Arcus Biosciences (RCUS) CAO receives RSU and stock option awards

Rhea-AI Filing Summary

Arcus Biosciences Chief Accounting Officer Alexander Azoy received new equity awards in the form of restricted stock units and stock options. On January 23, 2026, he was granted 21,050 shares of Common Stock as restricted stock units at a price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, as long as he continues serving the company.

On the same date, he also received a stock option to buy 14,050 shares of Common Stock at an exercise price of $22.13 per share, with no cost for the grant itself. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to his continued service. After these transactions, he beneficially owned 39,581 shares of Common Stock, including unvested RSUs, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Azoy Alexander

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		21,050(1)	A	$0	39,581(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$22.13	01/23/2026		A		14,050		(3)	01/22/2036	Common Stock	14,050	$0	14,050	D

Explanation of Responses:

1. Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.

2. Includes the unvested portion of the Reporting Person's RSU grants.

3. The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arcus Biosciences (RCUS) report for Alexander Azoy?

The filing shows that Chief Accounting Officer Alexander Azoy received equity compensation on January 23, 2026, consisting of a grant of 21,050 restricted stock units of Arcus Biosciences Common Stock and a stock option for 14,050 shares, with no purchase price for the grants themselves.

How many Arcus Biosciences (RCUS) shares does Alexander Azoy beneficially own after this Form 4?

Following the reported grants, Alexander Azoy beneficially owned 39,581 shares of Arcus Biosciences Common Stock. This figure includes the unvested portions of his restricted stock unit grants and is reported as direct ownership.

What are the vesting terms of the RSUs granted to Alexander Azoy at Arcus Biosciences (RCUS)?

The 21,050 restricted stock units granted to Alexander Azoy vest in four equal annual installments, starting on December 15, 2026. Vesting is conditioned on his continued service to Arcus Biosciences.

What are the key terms of the stock options granted to Alexander Azoy by Arcus Biosciences (RCUS)?

The stock option is described as a Stock Option (right to buy) covering 14,050 shares of Common Stock with an exercise price of $22.13 per share. It becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to Alexander Azoy’s continued service, and has an expiration date of January 22, 2036.

Did Alexander Azoy buy Arcus Biosciences (RCUS) shares on the open market in this Form 4?

No. The Form 4 reports grants of equity compensation: 21,050 restricted stock units and a stock option for 14,050 shares. Both are shown with a $0 transaction price, indicating they were awarded as compensation rather than purchased on the open market.

What role does Alexander Azoy hold at Arcus Biosciences (RCUS) according to this filing?

According to the filing, Alexander Azoy serves as the Chief Accounting Officer of Arcus Biosciences, Inc. and is the sole reporting person on this Form 4.